However, a recent biomarker study in patients with ovarian cancer treated with atezolizumab or placebo and standard chemotherapy found that deleterious mutations in RB1 were prognostic for a better PFS, regardless of the addition of atezolizumab (95). The gene discussed is RB1; the disease is ovarian cancer.